Bone Marrow Transplant for Leukaemia in India: Outcomes for Uzbekistan Patients

Understanding Bone Marrow Transplant for Leukaemia

A bone marrow transplant, more accurately called a hematopoietic stem cell transplant (HSCT), is an important treatment option for selected patients with leukaemia. The procedure replaces or restores blood-forming stem cells after intensive treatment and can allow the body to produce healthy blood cells again.

For many leukaemia patients, the transplant involves allogeneic transplantation, in which stem cells come from another person. The donor may be a matched sibling, an unrelated donor or, in selected circumstances, a partially matched family donor or another alternative donor. The choice depends on disease characteristics, donor availability, the patient’s health and the transplant team’s assessment.

India’s ICMR National Guidelines for Hematopoietic Cell Transplantation recognize transplantation as a standard-of-care or clinical option for selected leukemia settings, depending on disease type, remission status and donor availability. Importantly, the guidelines emphasize that even when transplantation is considered standard of care, it is not automatically the best option for every individual patient.

For Uzbekistan patients, this individualized approach is particularly important when deciding whether travelling to India for transplant is appropriate.

When Is a Transplant Recommended?

A transplant is generally considered when the expected benefit of replacing the patient’s diseased blood-forming system outweighs the substantial risks associated with transplantation. The decision can be influenced by the type of leukaemia, genetic and molecular characteristics, response to chemotherapy, remission status and risk of relapse.

For some patients with acute myeloid leukaemia (AML), transplantation may be considered after remission when the disease has features suggesting a significant risk of relapse. In acute lymphoblastic leukaemia (ALL), transplantation may similarly be considered in selected high-risk or relapsed cases.

The timing is therefore critical. A patient who reaches remission before transplant may have a different outlook from someone undergoing transplantation with active or resistant disease. ICMR’s national transplant guidelines specifically categorize indications according to disease type, remission status and donor category.

What Happens Before the Transplant?

Before travelling to India, the patient’s complete leukemia records should be collected. These may include bone marrow biopsy reports, flow-cytometry results, cytogenetic and molecular testing, chemotherapy records, blood counts, imaging when relevant and previous discharge summaries.

The Indian transplant team will reassess the disease and the patient’s general condition before confirming eligibility. This may include another bone marrow examination and additional molecular or genetic testing. The team also evaluates kidney, liver, heart and lung function because intensive transplant treatment places considerable demands on the body.

Donor evaluation is another major step. When a family member is a potential donor, human leukocyte antigen (HLA) testing is performed to assess compatibility. If a matched sibling is unavailable, the transplant team may consider an unrelated or alternative donor depending on the case.

How the Transplant Is Performed

Before receiving stem cells, the patient undergoes conditioning therapy. This usually involves chemotherapy, with or without radiation, designed to eliminate remaining malignant cells and suppress the immune system sufficiently for donor cells to establish themselves.

The donor stem cells are then infused through a central venous line. The procedure itself resembles a blood transfusion rather than an operation. The infused cells travel to the bone marrow and, over time, begin producing new blood cells.

The following weeks are a critical period. Blood counts remain low until the transplanted cells begin to establish themselves, a process known as engraftment. During this period, patients require close monitoring, infection prevention, transfusions when necessary and treatment for complications.

What Outcomes Can Uzbekistan Patients Expect?

There is no single outcome or survival percentage that applies to every leukaemia transplant patient. Outcomes depend on several factors, particularly the type of leukaemia, disease status at transplant, age, overall health, genetic risk, donor compatibility and complications following transplantation.

One of the most important predictors is disease status at the time of transplant. Patients who proceed to transplant after achieving an appropriate remission may have a different prognosis from those with persistent or relapsed disease. The patient’s transplant team should therefore explain expected outcomes using the individual’s actual leukemia characteristics rather than quoting a generalized hospital success rate.

The potential goal of allogeneic transplantation is long-term disease control or cure in appropriately selected patients. However, relapse remains possible even after successful engraftment, and long-term surveillance is essential.

Major Benefits and Risks

The potential benefit of transplant is the possibility of achieving durable remission in patients whose leukemia carries a significant risk of relapse with chemotherapy alone. In an allogeneic transplant, donor immune cells may also recognize and attack remaining leukemia cells, an effect known as the graft-versus-leukaemia effect.

At the same time, transplantation carries substantial risks. These include severe infections, bleeding, organ complications, graft-versus-host disease (GVHD), graft failure and relapse. GVHD occurs when donor immune cells attack the patient’s tissues and can affect the skin, digestive system, liver and other organs.

Because of these risks, transplant is performed in specialized centres with appropriate infrastructure, infection-control systems, blood-bank support, intensive care and experienced transplant teams. ICMR’s national guidelines specifically state that standard-of-care transplants should be undertaken in specialist centres with appropriate transplant expertise and infrastructure.

Recovery After Transplant in India

The early recovery period can be lengthy. Patients usually remain in or near the transplant centre while blood counts recover and the medical team monitors for infection, GVHD and other complications.

Nutrition, physical activity, psychological support and infection precautions become important during recovery. Some patients require repeated blood tests, transfusions or additional medicines for several weeks or months.

Uzbekistan families should not plan their return flight around a fixed number of days. The transplant team should decide when the patient is medically stable enough to travel. For many patients, remaining close to the transplant centre for an appropriate period after discharge is an important part of safe care.

Preparing to Return to Uzbekistan

Before leaving India, the patient should receive a complete transplant summary, including the diagnosis, conditioning regimen, donor information, transplant date, complications, medications, blood-test results and recommended follow-up schedule.

The family should also receive clear instructions about infection precautions, medicines, diet, vaccinations and symptoms that require urgent medical attention. Continued monitoring is essential after returning to Uzbekistan because some transplant complications can develop weeks or months later.

A local hematologist should ideally be identified before the patient leaves India. This allows routine blood testing and follow-up to continue without unnecessary interruption.

How Uzbekistan Patients Can Evaluate an Indian Transplant Centre

When comparing Indian hospitals, families should look beyond the advertised transplant number or claimed success rate. Important questions include the centre’s experience with the specific type of leukemia, transplant expertise, availability of HLA testing, donor options, infection-control facilities, intensive-care support, blood-bank services and management of GVHD and other complications.

Patients should also ask how the hospital manages follow-up for international patients after they return home. A transplant programme that can provide clear documentation and maintain communication with the patient’s hematologist in Uzbekistan can make long-term care more manageable.

India’s ICMR currently lists the National Guidelines for Hematopoietic Cell Transplantation among its official guidelines, providing a national framework for appropriate transplant practice.

Official Indian Government References

Indian Council of Medical Research (ICMR): ICMR’s National Guidelines for Hematopoietic Cell Transplantation provide an Indian framework for selecting patients for hematopoietic transplantation, including leukemia-related indications, donor categories and evidence levels. The guidelines also emphasize specialist transplant centres with appropriate infrastructure and experience.
ICMR – National Guidelines for Hematopoietic Cell Transplantation

Ministry of Health & Family Welfare (MoHFW), Government of India: MoHFW is India’s central ministry responsible for national health policy and major healthcare programmes. Its official resources provide broader information about India’s healthcare framework and public-health administration.
Ministry of Health & Family Welfare – Official Website

Our Commitment to Patients

Our mission is to place patients at the centre of every healthcare decision by providing trustworthy, evidence-based, and unbiased medical information. We believe that informed patients make better decisions. Backed by personalised guidance from our experienced advisory team, we help patients understand their treatment options, compare them objectively, and confidently choose the path that best aligns with their medical needs, personal preferences, and long-term health goals.

Dr. Dheeraj Bojwani
Medical Travel Advisor for International Patients Seeking Treatment in India
📍 New Delhi, India
🏆 24+ Years of Experience | Assisted 5,000+ International Patients
🌐 Website: www.indianhealthguru.com/en-uz/
📧 Email: contact@indianhealthguru.com

📞 Phone: +91 9156233611 | 📞 Alternate Phone: +91 9371136499

Disclaimer

This article is intended for educational and informational purposes only and should not be considered medical, legal, or visa advice. Medical recommendations, treatment plans, and procedures may vary from one patient to another based on individual health conditions and circumstances. Readers are strongly advised to consult qualified healthcare professionals before making any medical-related decisions.